JP2024521929A - ２，８－ジアザスピロ［４．５］デカン化合物 - Google Patents

２，８－ジアザスピロ［４．５］デカン化合物 Download PDF

Info

Publication number
JP2024521929A
JP2024521929A JP2023574635A JP2023574635A JP2024521929A JP 2024521929 A JP2024521929 A JP 2024521929A JP 2023574635 A JP2023574635 A JP 2023574635A JP 2023574635 A JP2023574635 A JP 2023574635A JP 2024521929 A JP2024521929 A JP 2024521929A
Authority
JP
Japan
Prior art keywords
alkyl
compound
optionally substituted
independently selected
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521929A5 (https=
JPWO2022253341A5 (https=
Inventor
スティーヴン ジョン マックケラル，
アリス ローズ ウォン，
ジェームズ ジョン クロフォード，
ウェンディー リー，
クン ワウ ライ，
ギヨーム ペルティエ，
ステファニー ロイ，
ダナ クリスティン ウィンター，
美樹子 奥村
ルース ドレル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2024521929A publication Critical patent/JP2024521929A/ja
Publication of JP2024521929A5 publication Critical patent/JP2024521929A5/ja
Publication of JPWO2022253341A5 publication Critical patent/JPWO2022253341A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Pens And Brushes (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
JP2023574635A 2021-06-04 2022-06-03 ２，８－ジアザスピロ［４．５］デカン化合物 Pending JP2024521929A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021098358 2021-06-04
CNPCT/CN2021/098358 2021-06-04
PCT/CN2022/097025 WO2022253341A1 (en) 2021-06-04 2022-06-03 2, 8-diazaspiro [4.5] decane compounds

Publications (3)

Publication Number Publication Date
JP2024521929A true JP2024521929A (ja) 2024-06-04
JP2024521929A5 JP2024521929A5 (https=) 2025-06-12
JPWO2022253341A5 JPWO2022253341A5 (https=) 2025-06-12

Family

ID=84322789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574635A Pending JP2024521929A (ja) 2021-06-04 2022-06-03 ２，８－ジアザスピロ［４．５］デカン化合物

Country Status (11)

Country Link
US (1) US20240174696A1 (https=)
EP (1) EP4347594A4 (https=)
JP (1) JP2024521929A (https=)
KR (1) KR20240016977A (https=)
CN (1) CN117425654A (https=)
AR (1) AR126078A1 (https=)
AU (1) AU2022284188A1 (https=)
BR (1) BR112023025393A2 (https=)
CA (1) CA3222054A1 (https=)
TW (1) TW202313608A (https=)
WO (1) WO2022253341A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523530A (ja) * 2007-04-06 2010-07-15 ノバルティス アーゲー タンパク質キナーゼ阻害剤として有益な［２，６］ナフチリジン
JP2020517698A (ja) * 2017-04-28 2020-06-18 ノバルティス アーゲー ６−６縮合二環式ヘテロアリール化合物及びｌａｔｓ阻害剤としてのその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011529932A (ja) * 2008-08-05 2011-12-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ナフチリジン及び医薬としてのその使用
WO2012167423A1 (en) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
KR20140048216A (ko) * 2011-06-29 2014-04-23 오츠카 세이야쿠 가부시키가이샤 치료 화합물로서의 퀴나졸린 및 관련된 사용 방법
TWI675836B (zh) * 2014-03-25 2019-11-01 美商伊格尼塔公司 非典型蛋白質激酶ｃ之氮雜喹唑啉抑制劑
KR102328435B1 (ko) * 2018-09-11 2021-11-18 재단법인 대구경북첨단의료산업진흥재단 신규 피리도-피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
WO2021050059A1 (en) * 2019-09-11 2021-03-18 Provincial Health Services Authority Dna-pk inhibiting compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010523530A (ja) * 2007-04-06 2010-07-15 ノバルティス アーゲー タンパク質キナーゼ阻害剤として有益な［２，６］ナフチリジン
JP2020517698A (ja) * 2017-04-28 2020-06-18 ノバルティス アーゲー ６−６縮合二環式ヘテロアリール化合物及びｌａｔｓ阻害剤としてのその使用

Also Published As

Publication number Publication date
CN117425654A (zh) 2024-01-19
TW202313608A (zh) 2023-04-01
AU2022284188A1 (en) 2023-11-30
WO2022253341A1 (en) 2022-12-08
AR126078A1 (es) 2023-09-06
EP4347594A1 (en) 2024-04-10
BR112023025393A2 (pt) 2024-02-27
KR20240016977A (ko) 2024-02-06
US20240174696A1 (en) 2024-05-30
EP4347594A4 (en) 2025-06-18
CA3222054A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
KR101862493B1 (ko) Fgfr4 억제제로서의 고리-융합된 비시클릭 피리딜 유도체
TW202321242A (zh) 雜環化合物及使用方法
TW202319056A (zh) Ｓｈｐ２抑制劑及其用途
TW202330536A (zh) 雜環類化合物、藥物組成物及其應用
TW202409030A (zh) 五元並六元含氮化物、其中間體、製備方法和應用
US20250195513A1 (en) Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of use
JP2021506979A (ja) ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアリール−ビピリジンアミン誘導体
EA024123B1 (ru) Тетрагидропиридопиримидиновые производные
NZ749946A (en) Novel compound or pharmaceutically acceptable salt thereof
JP7840334B2 (ja) 芳香族複素環式化合物、薬学的組成物、及びその使用
EP4303216A1 (en) Fused ring substituted six-membered heterocyclic compound, preparation method therefor and use thereof
CN121419983A (zh) 基于小脑蛋白的kras降解protac及其相关用途
CA3145043A1 (en) 2h-indazole derivatives and their use in the treatment of disease
EP3546458A1 (en) Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof
US20250214991A1 (en) Bicyclic heteroaryl-containing compounds as ikzf2 degraders
US20210363130A1 (en) Heterocyclic compound
CN120051470A (zh) 氮杂喹唑啉化合物及使用方法
US10377770B2 (en) Tricyclic compounds and compositions as kinase inhibitors
AU2019295983B2 (en) Tricyclic compounds
EP4051387A1 (en) Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
CN119654322A (zh) Tyk2抑制剂
JP2024521929A (ja) ２，８－ジアザスピロ［４．５］デカン化合物
JP2025528119A (ja) Ｊａｋ２阻害剤としての複素環式アミド及び尿素化合物
TW202345794A (zh) 依莫帕米結合蛋白抑制劑及其用途
HK40101182A (zh) 2,8-二氮杂螺[4.5]癸烷化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250604

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260317